Changes in chromatin accessibility and transcriptional landscape induced by HDAC inhibitors in TP53 mutated patient-derived colon cancer organoids - 22/03/24

Abstract |
Here we present the generation and characterization of patient-derived organoids (PDOs) from colorectal cancer patients. PDOs derived from two patients with TP53 mutations were tested with two different HDAC inhibitors (SAHA and NKL54). Cell death induction, transcriptome, and chromatin accessibility changes were analyzed. HDACIs promote the upregulation of low expressed genes and the downregulation of highly expressed genes. A similar differential effect is observed at the level of chromatin accessibility. Only SAHA is a potent inducer of cell death, which is characterized by the upregulation of BH3-only genes BIK and BMF. Up-regulation of BIK is associated with increased accessibility in an intronic region that has enhancer properties. SAHA, but not NKL54, also causes downregulation of BCL2L1 and decreases chromatin accessibility in three distinct regions of the BCL2L1 locus. Both inhibitors upregulate the expression of innate immunity genes and members of the MHC family. In summary, our exploratory study indicates a mechanism of action for SAHA and demonstrate the low efficacy of NKL54 as a single agent for apoptosis induction, using two PDOs. These observations need to be validated in a larger cohort of PDOs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Organoids from patients with colorectal carcinoma (CRC) were prepared and mutation status was determined. |
• | The HDACI SAHA induces apoptosis in TP53-mutated CRC organoids, while NKL54, a class I-specific inhibitor, is inefficient. |
• | HDACIs favor the accessibility to chromatin and expression of low-expressed genes. |
• | SAHA differentially affects chromatin accessibility in the regulatory regions of the apoptotic genes BIK and BCL2L1. |
Abbreviations : DiOC63, ATAC-seq, CG, CRC, HDACIs, DEGs, MHC, PDOs, SAHA, TF, TPM, TSS, 3D, 2D, WES.
Keywords : BCL2, Apoptosis, HDAC, TP53, MHC
Plan
Vol 173
Article 116374- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
